Vical Incorporated Stock Nasdaq
Equities
US9256022032
Biotechnology & Medical Research
Financials (USD)
Sales 2022 | 6.94M | Sales 2023 | 8.01M | Capitalization | 5.25M |
---|---|---|---|---|---|
Net income 2022 | -21M | Net income 2023 | -5M | EV / Sales 2022 | -0.59 x |
Net cash position 2022 | 8.63M | Net cash position 2023 | 10.87M | EV / Sales 2023 | -0.7 x |
P/E ratio 2022 |
-0.2
x | P/E ratio 2023 |
-0.83
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 98.4% |
Managers | Title | Age | Since |
---|---|---|---|
Albert Marchio
CEO | Chief Executive Officer | 72 | 20-11-30 |
Nancy Seretta
CTO | Chief Tech/Sci/R&D Officer | - | 15-12-31 |
Aaron Fox-Collis
AUD | Comptroller/Controller/Auditor | - | 20-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Albert Marchio
CEO | Chief Executive Officer | 72 | 20-11-30 |
1st Jan change | Capi. | |
---|---|---|
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |